Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naldemedine
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Prophylactic Naldemedine for Opioid-induced Nausea & Vomiting in Cancer Patients
Details : Naldemedine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Opioid-Induced Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2025
Lead Product(s) : Naldemedine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naldemedine
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
Details : Naldemedine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Opioid-Induced Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Naldemedine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naldemedine
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naldemedine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Postoperative Gastrointestinal Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : Naldemedine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable